Cargando…
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
To determine the value of tumor cell programmed death-ligand 1 (PD-L1) expression as a predictive biomarker of nivolumab monotherapy efficacy in treatment-naive patients with clear cell renal cell carcinoma (ccRCC) and the efficacy of salvage nivolumab/ipilimumab in patients with tumors unresponsive...
Autores principales: | Atkins, Michael B., Jegede, Opeyemi A., Haas, Naomi B., McDermott, David F., Bilen, Mehmet A., Stein, Mark, Sosman, Jeffrey A., Alter, Robert, Plimack, Elizabeth R., Ornstein, Moshe, Hurwitz, Michael, Peace, David J., Signoretti, Sabina, Denize, Thomas, Cimadamore, Alessia, Wu, Catherine J., Braun, David, Einstein, David, Catalano, Paul J., Hammers, Hans |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426835/ https://www.ncbi.nlm.nih.gov/pubmed/35442713 http://dx.doi.org/10.1200/JCO.21.02938 |
Ejemplares similares
-
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
por: Atkins, Michael B, et al.
Publicado: (2023) -
Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299
por: Dudek, Arkadiusz Z., et al.
Publicado: (2023) -
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021) -
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022) -
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab
por: McQuade, Jennifer L., et al.
Publicado: (2022)